HC Wainwright Issues Optimistic Forecast for COYA Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Analysts at HC Wainwright increased their Q3 2025 EPS estimates for shares of Coya Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.24) per share for the quarter, up from their previous estimate of ($0.50). The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.41) EPS.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.44). The company had revenue of $257.88 million for the quarter, compared to the consensus estimate of $2.63 million.

A number of other research analysts also recently commented on COYA. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, May 13th. D. Boral Capital reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday, April 22nd.

Coya Therapeutics Trading Down 1.8%

Shares of COYA opened at $5.86 on Wednesday. The company’s fifty day simple moving average is $6.02 and its 200 day simple moving average is $6.16. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $10.24. The company has a market cap of $98.01 million, a price-to-earnings ratio of -9.02 and a beta of 0.49.

Institutional Trading of Coya Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. DME Capital Management LP increased its position in Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after acquiring an additional 372,414 shares during the period. AIGH Capital Management LLC boosted its stake in shares of Coya Therapeutics by 85.0% in the fourth quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock valued at $6,883,000 after buying an additional 551,725 shares during the period. CM Management LLC grew its position in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $1,294,000 after buying an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC acquired a new stake in Coya Therapeutics during the first quarter worth approximately $1,083,000. Finally, Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock worth $863,000 after purchasing an additional 8,267 shares during the period. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.